[go: up one dir, main page]

MX2010002005A - Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa. - Google Patents

Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.

Info

Publication number
MX2010002005A
MX2010002005A MX2010002005A MX2010002005A MX2010002005A MX 2010002005 A MX2010002005 A MX 2010002005A MX 2010002005 A MX2010002005 A MX 2010002005A MX 2010002005 A MX2010002005 A MX 2010002005A MX 2010002005 A MX2010002005 A MX 2010002005A
Authority
MX
Mexico
Prior art keywords
raf
compounds
kinase inhibitors
heteroarylamino
abl
Prior art date
Application number
MX2010002005A
Other languages
English (en)
Inventor
Juliet Nabakka
Xiaolin Li
Jon Loren
Donatella Chianelli
Valentina Molteni
Xiaodong Liu
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MX2010002005A publication Critical patent/MX2010002005A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona compuestos de la fórmula (I): (ver fórmula I) y composiciones farmacéuticas de los mismos, los cuales son útiles como inhibidores de cinasa de proteína, así como métodos para utilizar tales compuestos con el fin de tratar, aminorar, o prevenir una condición asociada con una actividad de cinasa anormal o mal regulada. En algunas modalidades, la invención proporciona métodos para utilizar tales compuestos con el fin de tratar, aminorar, o prevenir enfermedades o trastornos que involucren una activación anormal de las cinasas c-kit, PDGFRa, PDGFRß, CSF1R, Abl, BCRAbl, CSK, JNK1, JNK2, p38, p70S6K, TGFß, SRC, EGFR, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2ß, BRK, Fms, KDR, c-raf o b-raf.
MX2010002005A 2007-08-22 2008-08-18 Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa. MX2010002005A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95724007P 2007-08-22 2007-08-22
PCT/US2008/073438 WO2009026204A1 (en) 2007-08-22 2008-08-18 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2010002005A true MX2010002005A (es) 2010-03-11

Family

ID=39930713

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002005A MX2010002005A (es) 2007-08-22 2008-08-18 Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.

Country Status (13)

Country Link
US (1) US8288540B2 (es)
EP (1) EP2190836B1 (es)
JP (1) JP5303557B2 (es)
KR (1) KR101171488B1 (es)
CN (1) CN101784539A (es)
AT (1) ATE520682T1 (es)
AU (1) AU2008289135B2 (es)
BR (1) BRPI0815572A2 (es)
CA (1) CA2697077C (es)
EA (1) EA017392B1 (es)
ES (1) ES2368876T3 (es)
MX (1) MX2010002005A (es)
WO (1) WO2009026204A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
WO2009026276A1 (en) 2007-08-22 2009-02-26 Irm Llc 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
EA020548B1 (ru) 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
MX346393B (es) 2009-12-17 2017-03-17 Centrexion Therapeutics Corp Nuevos antagonistas del receptor ccr2 y usos de los mismo.
JP5646736B2 (ja) 2010-05-12 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
EP2576542B1 (en) 2010-05-25 2015-04-22 Boehringer Ingelheim International GmbH Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases
WO2011151251A1 (en) * 2010-06-01 2011-12-08 Boehringer Ingelheim International Gmbh New ccr2 antagonists
UA112061C2 (uk) 2010-07-29 2016-07-25 Райджел Фармасьютікалз, Інк. Активуючі ampk гетероциклічні сполуки і способи їх використання
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
CA2842976A1 (en) 2011-07-26 2013-01-31 Grunenthal Gmbh Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
US9815815B2 (en) 2013-01-10 2017-11-14 Pulmokine, Inc. Non-selective kinase inhibitors
CA2921805C (en) 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
CN104458675A (zh) * 2013-09-12 2015-03-25 中国药科大学 一种筛选干细胞因子受体激酶抑制剂高通量筛选方法
CN104458674A (zh) * 2013-09-12 2015-03-25 中国药科大学 一种筛选血管内皮生长因子1激酶抑制剂高通量筛选方法
EP3054937B1 (en) 2013-10-11 2023-07-26 Pulmokine, Inc. Spray dry formulations
ES2902533T3 (es) 2013-11-21 2022-03-28 Brigham & Womens Hospital Inc Composiciones y métodos para tratar la hipertensión pulmonar
CA2956256A1 (en) 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
WO2017004537A1 (en) 2015-07-02 2017-01-05 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
US9890163B2 (en) 2015-10-15 2018-02-13 Princeton Drug Discovery Inc Inhibitors of protein kinases
EP3481753B1 (en) * 2016-07-06 2020-11-04 Tomra Systems ASA Device and method for singulation of used beverage or food containers
JP2020500183A (ja) 2016-10-27 2020-01-09 プルモキネ、インコーポレイテッド 肺高血圧症の治療のための併用療法
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
CN110546145B (zh) * 2017-05-24 2020-07-31 上海和誉生物医药科技有限公司 一种氮杂芳基衍生物、其制备方法和在药学上的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0164204A1 (en) 1984-05-12 1985-12-11 FISONS plc Novel pharmaceutically useful pyrimidines
CA2148931A1 (en) 1993-10-01 1995-04-13 Jurg Zimmermann Pyrimidineamine derivatives and processes for the preparation thereof
JP2002532953A (ja) * 1998-12-08 2002-10-02 グローブスパン ヴィラタ、インコーポレイテッド 時間デュープレックス雑音環境において動作しているａｄｓｌシステム用の代替構成
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
ATE331519T1 (de) * 2001-05-16 2006-07-15 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
WO2003011836A1 (en) * 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7117491B2 (en) * 2002-08-29 2006-10-03 International Business Machines Corporation Method, system, and program for determining whether data has been modified
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
ES2229928B1 (es) 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
ES2390227T3 (es) 2004-09-09 2012-11-07 Natco Pharma Limited Nuevos derivados de fenilaminopirimidina como inhibidores de la BCR-ABL kinasa
CA2580913A1 (en) * 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
EP1836173A4 (en) 2004-12-23 2009-07-08 Deciphera Pharmaceuticals Llc ANTI-INFLAMMATORY DRUGS
AU2005321946B2 (en) 2004-12-23 2012-08-16 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
MX2007011500A (es) 2005-03-16 2007-11-21 Targegen Inc Compuestos pirimidina y metodos de uso.
KR100674813B1 (ko) 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
KR101415426B1 (ko) * 2005-09-27 2014-07-04 아이알엠 엘엘씨 디아릴아민-함유 화합물 및 조성물, 및 ｃ-ｋｉｔ 수용체의조절제로서의 그의 용도
CA2628474A1 (en) * 2005-11-03 2007-05-10 Sgx Pharmaceuticals, Inc. Pyrimidinyl-thiophene kinase modulators
BRPI0718677A2 (pt) 2006-11-03 2013-11-26 Irm Llc Compostos e composições como inibidores de quinases proteicas
CA2686378C (en) 2007-05-04 2012-07-24 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
EA019524B1 (ru) 2007-05-04 2014-04-30 Айрм Ллк СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ с-kit И PDGFR
WO2009026276A1 (en) 2007-08-22 2009-02-26 Irm Llc 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors

Also Published As

Publication number Publication date
AU2008289135B2 (en) 2012-02-23
KR20100050554A (ko) 2010-05-13
CN101784539A (zh) 2010-07-21
US8288540B2 (en) 2012-10-16
EA201000325A1 (ru) 2010-10-29
WO2009026204A1 (en) 2009-02-26
US20110053952A1 (en) 2011-03-03
CA2697077A1 (en) 2009-02-26
EP2190836B1 (en) 2011-08-17
EA017392B1 (ru) 2012-12-28
JP2010536865A (ja) 2010-12-02
EP2190836A1 (en) 2010-06-02
ES2368876T3 (es) 2011-11-23
JP5303557B2 (ja) 2013-10-02
CA2697077C (en) 2012-10-16
ATE520682T1 (de) 2011-09-15
KR101171488B1 (ko) 2012-08-07
AU2008289135A1 (en) 2009-02-26
BRPI0815572A2 (pt) 2015-02-18

Similar Documents

Publication Publication Date Title
MX2010002005A (es) Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.
MX2009004141A (es) Composiciones y metodos para modular receptores de c-kit y pdgfr.
TN2010000087A1 (en) 5-(4- haloalkoxy) phenyl pyrimidine -2- aminecompounds and compositons as kinase inhibitors
TNSN06406A1 (en) Compounds and compositions as protein kinase inhibitors
TW200637547A (en) Compounds and compositions as protein kinase inhibitors
MX2009003456A (es) Compuestos y composiciones como inhibidores de proteina cinasa.
WO2005034869A3 (en) Compounds and compositions as protein kinase inhibitors
MX2008002165A (es) Compuestos y composiciones como inhibidores de la proteina cinasa.
PL2027123T3 (pl) Związki i kompozycje jako inhibitory kinaz białkowych
MX2009013782A (es) Inhibidores de cinasa de proteina y metodos para el uso de los mismos.
EA201000003A1 (ru) Ингибиторы протеинкиназ и способы их применения
TN2014000068A1 (en) Compounds and compositions as c-kit kinase inhibitors
TN2014000061A1 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
WO2008112695A3 (en) Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
MY182533A (en) Benzoxazole kinase inhibitors and method of use
WO2006124731A3 (en) Compounds and compositions as protein kinase inhibitors
WO2005039486A3 (en) Compounds and compositions as protein kinase inhibitors
WO2005030151A3 (en) Compounds and compositions as protein kinase inhibitors
TH98294A (th) องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์
DOP2009000083A (es) Composiciones y metodos para modular recpetores de pdgfr y c-kit

Legal Events

Date Code Title Description
FG Grant or registration